Hansa Biopharma is seeking approval for its drug Idefirix in various markets, with SERB handling commercialization in EU member states.
4 reports, 2 independent
Updated Oct 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hansa Biopharma is seeking approval for its drug Idefirix in various markets, with SERB handling commercialization in EU member states.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Idefirix by Hansa Biopharma is now approved in the EU.1 source
- Hansa Biopharma received its first commercial patient for the drug in Australia.Sub-event
Hansa Biopharma seeks EMA approval for Idefirix, outlining commercialization plans in the EU.1 source
Keep exploring
The entities involved
-
Hansa Biopharma
company in Lund, Sweden
Nothing else this week.
-
European Medicines Agency
highest regulatory authority on medicines in the European Union